ChromaDex (NASDAQ:CDXC) Stock Crosses Above 200 Day Moving Average of $1.64

ChromaDex Co. (NASDAQ:CDXC – Get Free Report) passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.64 and traded as high as $1.64. ChromaDex shares last traded at $1.61, with a volume of 53,149 shares trading hands.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on CDXC. StockNews.com upgraded ChromaDex from a “buy” rating to a “strong-buy” rating in a research report on Friday, June 30th. LADENBURG THALM/SH SH reduced their price target on ChromaDex from $7.50 to $6.60 in a research report on Thursday, May 11th.

Get ChromaDex alerts:

ChromaDex Stock Up 6.2 %

The company has a 50-day moving average of $1.60 and a 200 day moving average of $1.63. The firm has a market capitalization of $128.19 million, a PE ratio of -11.40 and a beta of 1.80.

ChromaDex (NASDAQ:CDXC – Get Free Report) last posted its earnings results on Wednesday, May 10th. The company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.05) by $0.02. ChromaDex had a negative return on equity of 51.99% and a negative net margin of 13.84%. The business had revenue of $22.56 million during the quarter, compared to analysts’ expectations of $19.37 million. As a group, equities analysts anticipate that ChromaDex Co. will post -0.14 EPS for the current fiscal year.

Hedge Funds Weigh In On ChromaDex

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CDXC. Bank of America Corp DE grew its position in ChromaDex by 130.4% during the first quarter. Bank of America Corp DE now owns 16,469 shares of the company’s stock worth $25,000 after buying an additional 9,321 shares in the last quarter. Virtu Financial LLC purchased a new position in shares of ChromaDex in the 1st quarter worth about $27,000. Squarepoint Ops LLC purchased a new position in shares of ChromaDex in the 1st quarter worth about $28,000. International Assets Investment Management LLC purchased a new position in shares of ChromaDex in the 4th quarter worth about $34,000. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of ChromaDex by 74.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 39,300 shares of the company’s stock worth $66,000 after purchasing an additional 16,800 shares in the last quarter. 15.80% of the stock is currently owned by hedge funds and other institutional investors.

About ChromaDex

(Get Free Report)

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.

Read More

• Five stocks we like better than ChromaDex
• Dividend Tax Calculator
• Is AI On The Verge Of A Monster Short Squeeze Breakout?
• What are stock market earnings reports?
• Chipotle Mexican Grill Serves Up Another Entry Point 
• What Are Utility Stocks? An Overview of the Utilities Sector
• 7 Best Hotel REITs to Buy Now

Receive News & Ratings for ChromaDex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex and related companies with MarketBeat.com's FREE daily email newsletter.